108088-19-3 Usage
General Description
8-Methoxy-chroman-3-carboxylic acid is a chemical compound with the molecular formula C11H10O5. It is a derivative of chroman, a natural compound found in many plants. This chemical is used in the pharmaceutical industry for its potential medicinal properties, particularly as an antioxidant and anti-inflammatory agent. It has also been studied for its potential applications in the treatment of various diseases and conditions, including cancer, cardiovascular diseases, and neurological disorders. The compound has shown promising results in some preclinical studies, indicating its potential as a therapeutic agent. Additionally, research has been conducted on its potential use in skincare and cosmetic products due to its antioxidant properties.
Check Digit Verification of cas no
The CAS Registry Mumber 108088-19-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,8,0,8 and 8 respectively; the second part has 2 digits, 1 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 108088-19:
(8*1)+(7*0)+(6*8)+(5*0)+(4*8)+(3*8)+(2*1)+(1*9)=123
123 % 10 = 3
So 108088-19-3 is a valid CAS Registry Number.
InChI:InChI=1/C11H12O4/c1-14-9-4-2-3-7-5-8(11(12)13)6-15-10(7)9/h2-4,8H,5-6H2,1H3,(H,12,13)
108088-19-3Relevant articles and documents
The development of benzimidazoles as selective rho kinase inhibitors
Sessions, E. Hampton,Smolinski, Michael,Wang, Bo,Frackowiak, Bozena,Chowdhury, Sarwat,Yin, Yan,Chen, Yen Ting,Ruiz, Claudia,Lin, Li,Pocas, Jennifer,Schr?ter, Thomas,Cameron, Michael D.,LoGrasso, Philip,Feng, Yangbo,Bannister, Thomas D.
scheme or table, p. 1939 - 1943 (2010/09/03)
Rho Kinase (ROCK) is a serine/threonine kinase whose inhibition could prove beneficial in numerous therapeutic areas. We have developed a promising class of ATP-competitive inhibitors based upon a benzimidazole scaffold, which show excellent potency toward ROCK (IC50 10 nM). This report details the optimization of selectivity for ROCK over other related kinases such as Protein kinase A (PKA).
